Close Menu

NEW YORK – Molecular diagnostics developer Curetis said on Thursday that its preliminary revenues for fiscal year 2019 rose 64 percent to €2.3 million ($2.5 million) from €1.4 million in 2018.

The company said that this revenue was realized from a total contract order volume of about €3.4 million received in 2019 compared to contract order volume of €1.1 million in 2018. Revenue growth in 2019 was primarily driven by collaborations undertaken by Curetis subsidiary Ares Genetics, as well as increased uptake of Curetis' Unyvero product line, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.